Last reviewed · How we verify
Anktiva
Anktiva is a Small molecule drug developed by ImmunityBio, Inc.. It is currently FDA-approved. Also known as: N-803, Nogapendekin Alfa Inbakicept, NAI.
At a glance
| Generic name | Anktiva |
|---|---|
| Also known as | N-803, Nogapendekin Alfa Inbakicept, NAI |
| Sponsor | ImmunityBio, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Anktiva in Patients With Long Covid-19. (PHASE2)
- Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia (PHASE3)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer (PHASE1)
- PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC (PHASE2)
- N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (PHASE2)
- Interleukin-15 to Promote Post-ART Control of HIV (PHASE2)
- First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anktiva CI brief — competitive landscape report
- Anktiva updates RSS · CI watch RSS
- ImmunityBio, Inc. portfolio CI
Frequently asked questions about Anktiva
What is Anktiva?
Anktiva is a Small molecule drug developed by ImmunityBio, Inc..
Who makes Anktiva?
Anktiva is developed and marketed by ImmunityBio, Inc. (see full ImmunityBio, Inc. pipeline at /company/immunitybio-inc).
Is Anktiva also known as anything else?
Anktiva is also known as N-803, Nogapendekin Alfa Inbakicept, NAI.
What development phase is Anktiva in?
Anktiva is FDA-approved (marketed).
Related
- Manufacturer: ImmunityBio, Inc. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: N-803, Nogapendekin Alfa Inbakicept, NAI